ABOS

Acumen Pharmaceuticals Inc

0.2397

Nov 02 • 3:59 PM ET +0.0296 (14.09%)

0.2226

Aftermarket • 7:59 PM ET -0.0171 (-7.13%)

Healthcare Biotechnology USA Nano NASD

Nov 02, 6:32 PMNo clear catalyst identified; ABOS rebounds 14% after Friday trial-failure crash

Peers: PRTA ACIU KRSA CGTX ANVS AVXL ALEC FLNA DNLI ALZN

| Held by: VTI VXF VTWO DFAS IWM VTWV IWN DFMC IWC DXUV

Scroll to Statements

Index	RUT
Market Cap	17.34M
Enterprise Value	-34.95M
Income	-103.96M
Sales	0.00M
Book/sh	0.48
Cash/sh	1.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	61
IPO	Jul 01, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.50
P/C	0.22
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.89
Current Ratio	1.89
Debt/Eq	0.76
LT Debt/Eq	0.17
Option/Short	Yes / Yes

EPS (ttm)	-1.55
EPS next Y	-0.72
EPS next Q	-0.38
EPS this Y	24.29%
EPS next Y	52.35%
EPS next 5Y	50.45%
EPS past 3/5Y	-23.82% -61.49%
Sales past 3/5Y	- -
EPS Y/Y TTM	29.92%
Sales Y/Y TTM	-
EPS Q/Q	19.67%
Sales Q/Q	-
Earnings	Oct 26 BMO
EPS/Sales Surpr.	9.93% -

Insider Own	14.60%
Insider Trans	-0.37%
Inst Own	58.75%
Inst Trans	3.54%
ROA	-91.28%
ROE	-162.72%
ROIC	-256.84%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-86.98%
SMA50	-89.79%
SMA200	-90.39%
Trades

Shs Outstand	72.33M
Shs Float	61.76M
Short Float	5.00%
Short Ratio	1.98
Short Interest	3.09M
52W High	3.60 -93.34%
52W Low	0.21 14.58%
Volatility	27.33% 13.03%
ATR (14)	0.31
RSI (14)	21.07
Beta	0.51
Rel Volume	21.61
Avg Volume	1.56M
Volume	33,717,984

Perf Week	-89.44%
Perf Month	-88.25%
Perf Quarter	-89.30%
Perf Half Y	-90.33%
Perf YTD	-88.64%
Perf Year	-89.15%
Perf 3Y	-87.77%
Perf 5Y	-98.23%
Perf 10Y	-
Recom	3.17
Target Price	1.00
Prev Close	0.21
Price	0.24
Change %	14.09%

Consensus

Hold

Avg. Price Target

$1.00

Implied Upside

+317.2%

Analysts9incl. previous ratings

Rating Distribution7 Buy · 1 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 02, 2026	Downgrade	BBofA Securities	Buy → Underperform	$1	+317.2%
Oct 30, 2026	Downgrade	SStifel	Buy → Hold	$1	+317.2%
Jun 17, 2025	Initiated	CCitigroup	Buy	$4	+1,568.8%
Jul 26, 2024	Initiated	CCitigroup	Buy	$7	+2,820.3%
Dec 12, 2023	Initiated	DDeutsche Bank	Buy	$8	+3,237.5%
Jul 20, 2023	Resumed	BBofA Securities	Buy	$9 → $14	+5,740.6%
May 18, 2023	Initiated	CCantor Fitzgerald	Overweight	$13	+5,323.4%
Jul 15, 2022	Initiated	BBTIG Research	Buy	$15	+6,157.8%
Jun 30, 2022	Initiated	HH.C. Wainwright	Buy	$15	+6,157.8%
Jan 21, 2022	Upgrade	BBofA Securities	Neutral → Buy	$16 → $14	+5,740.6%
Jul 26, 2021	Initiated	UUBS	Buy	$27	+11,164.1%
Jul 26, 2021	Initiated	SStifel	Buy	$27	+11,164.1%
Jul 26, 2021	Initiated	CCredit Suisse	Outperform	$26	+10,746.9%
Jul 26, 2021	Initiated	BBofA Securities	Neutral	$20	+8,243.8%

Oct-30-26 07:00AM	Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint (GlobeNewswire) -90.83%
Oct-26-26 10:09AM	Acumen Pharmaceuticals Reports Smaller Q3 Loss, Shares Rise as Phase 2 Alzheimer's Data Approach (InvestorsHub) +14.65%
09:57AM	Acumen Beats On A Share-Count-Aided Loss, But November's Binary Sabirnetug Readout And A Thin Cash Runway Are The Real Story (Earnings Whispers)
08:07AM	Acumen Pharmaceuticals beats Q3 estimates, shares jump 6% (Investing.com)
07:00AM	Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
07:30AM	Loading…
Oct-22-26 07:30AM	Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
Oct-19-26 04:00PM	Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 (GlobeNewswire) +13.84%
Sep-10-26 04:00PM	Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 (GlobeNewswire)
Sep-02-26 04:00PM	Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.16%
Aug-12-26 07:04PM	Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ... (GuruFocus.com)
07:00AM	Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
Aug-05-26 04:00PM	Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 (GlobeNewswire)
Jul-20-26 12:15PM	VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform (Exec Edge)
Jul-16-26 12:18PM	Slate Medicines Appoints Mark W. Hahn to Board of Directors (Exec Edge)
Jul-15-26 11:23AM	Acumen Pharmaceuticals Shows Early Alzheimer's Disease Insights (Exec Edge) -12.25%
07:30AM	Loading…
07:30AM	Acumen Pharmaceuticals Highlights Enhanced Brain Delivery (EBD) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC) 2026 (GlobeNewswire)
Jul-07-26 07:30AM	Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery (EBD) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC) 2026 (GlobeNewswire)
Jun-16-26 06:18PM	Acumen Nominates 2 Therapies to Treat Alzheimers Disease (Exec Edge)
07:30AM	Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery (EBD) Development Candidates for the Treatment of Alzheimer's Disease (GlobeNewswire)
May-12-26 03:01PM	Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
07:00AM	Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
May-07-26 04:00PM	Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference (GlobeNewswire)
May-05-26 04:00PM	Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 (GlobeNewswire)
Mar-26-26 03:00PM	Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
07:00AM	Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights (GlobeNewswire)
Mar-19-26 04:00PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 (GlobeNewswire) -8.56%
Mar-17-26 05:41PM	Acumen Pharma Presents Brain Delivery Studies at Alzheimers and Parkinsons Diseases Conference 2026 (Exec Edge) -7.49% -5.50%
08:00AM	Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 (GlobeNewswire)
Mar-16-26 06:30AM	Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio (GlobeNewswire)
Mar-10-26 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum (GlobeNewswire) +7.01%
08:00AM	Loading…
Mar-03-26 08:00AM	Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 (GlobeNewswire)
Jan-25-26 06:05AM	Analysts Predict Up to 400% Spike for These 2 Strong Buy Penny Stocks (TipRanks)
Dec-02-25 05:54PM	Acumen Pharmaceuticals Presents Results on Alzheimers Disease at Conference (Exec Edge) -7.89% +10.29%
08:00AM	Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
Nov-18-25 08:00AM	Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +5.06%
Nov-17-25 08:00AM	Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease (GlobeNewswire) -8.67%
Nov-12-25 04:01PM	Acumen Pharmaceuticals Inc (ABOS) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -7.18%
07:00AM	Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Nov-10-25 08:00AM	Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors (GlobeNewswire)
Nov-05-25 04:00PM	Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire) -6.40%
Nov-04-25 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire) -11.01%
Aug-26-25 04:00PM	Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 07:00AM	Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.27%
Aug-05-25 04:00PM	Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-28-25 08:00AM	Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025 (GlobeNewswire) -7.01%
Jul-16-25 05:04AM	Acumen and JCR partner on brain delivery therapy for Alzheimers (Pharmaceutical Technology) +5.34%
Jul-15-25 07:00AM	JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimers Disease, Enabled by J-Brain Cargo® Technology Platform (Business Wire) -12.08%
07:00AM	Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimer's Disease (GlobeNewswire)
Jul-10-25 08:00AM	Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC) 2025 (GlobeNewswire)
May-21-25 04:52AM	Philanthropy CEO: Silicon Valley entrepreneurs who think they can cure poverty are a red flag (Fortune)
04:52AM	Acumen CEO: Entrepreneurs who think they can cure poverty with the Silicon Valley model are a red flag (Fortune)
May-14-25 03:06AM	Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com) -6.67%
May-13-25 10:30PM	Q1 2025 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-07-25 04:00PM	Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference (GlobeNewswire)
May-06-25 04:00PM	Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-02-25 07:00AM	Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting (GlobeNewswire)
Apr-01-25 07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-28-25 03:01AM	Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
01:00AM	Q4 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-25 10:05AM	Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript (SeekingAlpha) +6.03%
08:22AM	Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimers (Clinical Trials Arena)
07:00AM	Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights (GlobeNewswire)
Mar-26-25 08:00AM	Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease (GlobeNewswire)
Mar-20-25 04:00PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 (GlobeNewswire) -7.09%
Mar-19-25 08:00AM	Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers (GlobeNewswire)
Mar-18-25 08:48AM	Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimers (GlobeNewswire)
Mar-12-25 08:00AM	Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-10-25 04:00PM	Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.83%
Jan-10-25 08:05AM	Acumen announces Phase 1 INTERCEPT-AD study publication (TipRanks)
Jan-09-25 08:00AM	Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings (GlobeNewswire)
Nov-26-24 04:00PM	Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -6.78%
Nov-13-24 02:06AM	Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) -5.42%
Nov-12-24 10:54PM	Q3 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -16.93%
07:00AM	Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Nov-11-24 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire)
Nov-06-24 04:00PM	Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference (GlobeNewswire) +7.67%
08:00AM	Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality (GlobeNewswire)
Nov-05-24 04:00PM	Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 (GlobeNewswire)
Oct-31-24 08:05AM	Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (GlobeNewswire)
Oct-23-24 08:00AM	Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
Sep-30-24 04:00PM	Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference (GlobeNewswire)
Sep-27-24 07:46AM	Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug (Pharmaceutical Business Review)
Sep-26-24 08:00AM	Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease (GlobeNewswire)
Sep-25-24 04:00PM	Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 (GlobeNewswire)
Sep-03-24 04:00PM	Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference (GlobeNewswire) -10.58%
Aug-13-24 11:26PM	Q2 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +8.20% -9.21%
07:00AM	Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-06-24 04:00PM	Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024 (GlobeNewswire) -7.32%
Jul-29-24 07:00AM	Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease (GlobeNewswire) -5.46%
Jul-28-24 07:30AM	Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire)
Jul-11-24 08:00AM	Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire) +14.41%
Jun-21-24 11:13AM	Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
May-15-24 03:00AM	Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
02:06AM	Q1 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 11:53AM	ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +9.82%
07:00AM	Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-13-24 04:00PM	Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
10:15AM	Arthur J. Gallagher Acquires Acumen Advisors (MT Newswires)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Porter Derrell	Director	Jun 17 '26	Option Exercise	1.07	13,040	13,953	48,540	Jun 17 05:10 PM
Porter Derrell	Director	Jun 15 '26	Option Exercise	1.07	6,460	6,912	54,760	Jun 17 05:10 PM
Porter Derrell	Director	Jun 17 '26	Sale	2.33	13,040	30,318	35,500	Jun 17 05:10 PM
Porter Derrell	Director	Jun 16 '26	Sale	2.33	12,800	29,773	35,500	Jun 17 05:10 PM
Porter Derrell	Director	Jun 15 '26	Sale	2.35	6,460	15,149	48,300	Jun 17 05:10 PM
DERRELL PORTER	Director	Jun 17 '26	Proposed Sale	2.33	13,040	30,323		Jun 17 04:02 PM
DERRELL PORTER	Director	Jun 16 '26	Proposed Sale	2.33	12,800	29,768		Jun 16 05:03 PM
DERRELL PORTER	Director	Jun 15 '26	Proposed Sale	2.35	6,460	15,149		Jun 15 06:31 PM
Fountain Nathan B	Director	Jun 09 '26	Sale	2.23	6,400	14,273	48,150	Jun 10 04:51 PM
NATHAN FOUNTAIN	Director	Jun 09 '26	Proposed Sale	2.23	6,400	14,273		Jun 09 04:15 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Mar 06 '26	Option Exercise	1.85	2,090	3,866	176,089	Mar 10 09:45 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Mar 06 '26	Sale	3.26	2,090	6,813	173,999	Mar 10 09:45 PM
Meisner Derek M	Officer	Mar 06 '26	Proposed Sale	3.22	2,090	6,730		Mar 06 04:51 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Feb 27 '26	Option Exercise	1.85	9,406	17,401	183,405	Mar 03 09:42 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Feb 27 '26	Sale	3.01	9,406	28,311	173,999	Mar 03 09:42 PM
Meisner Derek M	Officer	Feb 27 '26	Proposed Sale	3.01	9,406	28,311		Feb 27 04:54 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 26 '26	Option Exercise	1.85	15,085	27,907	189,084	Jan 28 07:50 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 28 '26	Option Exercise	1.85	2,671	4,941	176,670	Jan 28 07:50 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 26 '26	Sale	3.00	15,085	45,263	173,999	Jan 28 07:50 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 28 '26	Sale	3.00	2,671	8,017	173,999	Jan 28 07:50 PM
Meisner Derek M	Officer	Jan 28 '26	Proposed Sale	3.00	2,671	8,017		Jan 28 04:05 PM
Meisner Derek M	Officer	Jan 27 '26	Proposed Sale	3.00	15,085	45,262		Jan 26 04:52 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 23 '26	Sale	1.90	5,633	10,718	173,999	Jan 23 06:12 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 21 '26	Sale	1.81	2,247	4,063	180,686	Jan 23 06:12 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 22 '26	Sale	1.84	1,054	1,939	179,632	Jan 23 06:12 PM
Siemers Eric	Chief Medical Officer	Jan 21 '26	Sale	1.80	2,331	4,204	256,266	Jan 23 06:12 PM
Siemers Eric	Chief Medical Officer	Jan 22 '26	Sale	1.82	895	1,629	255,371	Jan 23 06:12 PM
Zuga Matt	CFO & Chief Business Officer	Jan 21 '26	Sale	1.81	2,473	4,469	306,611	Jan 23 06:11 PM
Zuga Matt	CFO & Chief Business Officer	Jan 22 '26	Sale	1.86	1,687	3,138	304,924	Jan 23 06:11 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 21 '26	Sale	1.81	9,346	16,927	883,964	Jan 23 06:10 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 22 '26	Sale	1.88	2,689	5,066	881,275	Jan 23 06:10 PM
Barton Russell	Chief Operating Officer	Jan 21 '26	Sale	1.81	2,315	4,181	205,554	Jan 23 06:10 PM
Barton Russell	Chief Operating Officer	Jan 22 '26	Sale	1.84	462	850	205,092	Jan 23 06:10 PM
Meisner Derek M	Officer	Jan 23 '26	Proposed Sale	1.86	5,633	10,493		Jan 23 04:01 PM
Meisner Derek M	Officer	Jan 22 '26	Proposed Sale	1.84	1,054	1,939		Jan 22 04:16 PM
Siemers Eric	Officer	Jan 22 '26	Proposed Sale	1.82	895	1,629		Jan 22 04:16 PM
Barton Russell	Officer	Jan 22 '26	Proposed Sale	1.84	462	850		Jan 22 04:15 PM
Zuga Matt	Officer	Jan 22 '26	Proposed Sale	1.86	1,687	3,138		Jan 22 04:14 PM
OConnell Daniel Joseph	Officer	Jan 22 '26	Proposed Sale	1.88	2,689	5,066		Jan 22 04:13 PM
Meisner Derek M	Officer	Jan 21 '26	Proposed Sale	1.81	2,247	4,063		Jan 21 04:46 PM
Siemers Eric	Officer	Jan 21 '26	Proposed Sale	1.80	2,331	4,204		Jan 21 04:44 PM
Barton Russell	Officer	Jan 21 '26	Proposed Sale	1.81	2,315	4,181		Jan 21 04:37 PM
Zuga Matt	Officer	Jan 21 '26	Proposed Sale	1.81	2,473	4,469		Jan 21 04:34 PM
OConnell Daniel Joseph	Officer	Jan 21 '26	Proposed Sale	1.81	9,346	16,927		Jan 21 04:30 PM
Zuga Matt	CFO & Chief Business Officer	Jan 08 '26	Sale	1.82	6,888	12,513	209,951	Jan 12 06:52 PM
Barton Russell	Chief Operating Officer	Jan 08 '26	Sale	1.86	3,530	6,562	123,269	Jan 12 06:52 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 08 '26	Sale	1.82	36,911	67,246	97,548	Jan 12 06:51 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 12 '26	Sale	1.71	8,548	14,658	83,800	Jan 12 06:51 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 09 '26	Sale	1.76	5,200	9,169	92,348	Jan 12 06:51 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 09 '26	Sale	1.76	12,941	22,832	598,898	Jan 12 06:50 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 08 '26	Sale	1.82	8,143	14,815	611,839	Jan 12 06:50 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 12 '26	Sale	1.73	5,388	9,307	593,510	Jan 12 06:50 PM
Meisner Derek M	Officer	Jan 12 '26	Proposed Sale	1.71	8,548	14,658		Jan 12 04:03 PM
OConnell Daniel Joseph	Officer	Jan 12 '26	Proposed Sale	1.73	5,388	9,307		Jan 12 04:02 PM
Doherty James J.	President and CDO	Jan 08 '26	Sale	1.82	6,467	11,769	54,033	Jan 09 04:39 PM
Doherty James J.	President and CDO	Jan 07 '26	Sale	1.99	1,700	3,379	60,500	Jan 09 04:39 PM
Schacterle Amy	Chief Regulatory Officer	Jan 07 '26	Sale	1.98	1,097	2,176	7,703	Jan 09 04:38 PM
Meisner Derek M	Officer	Jan 09 '26	Proposed Sale	1.76	5,200	9,169		Jan 09 04:22 PM
OConnell Daniel Joseph	Officer	Jan 09 '26	Proposed Sale	1.76	12,941	22,832		Jan 09 04:20 PM
Doherty James J.	Officer	Jan 08 '26	Proposed Sale	1.82	6,467	11,769		Jan 08 05:15 PM
Meisner Derek M	Officer	Jan 08 '26	Proposed Sale	1.82	36,911	67,244		Jan 08 05:02 PM
Barton Russell	Officer	Jan 08 '26	Proposed Sale	1.86	3,530	6,562		Jan 08 04:49 PM
Zuga Matt	Officer	Jan 08 '26	Proposed Sale	1.82	6,888	12,513		Jan 08 04:34 PM
OConnell Daniel Joseph	Officer	Jan 08 '26	Proposed Sale	1.82	8,143	14,815		Jan 08 04:31 PM
Zuga Matt	CFO & Chief Business Officer	Jan 07 '26	Sale	1.99	5,805	11,566	216,839	Jan 07 09:31 PM
Zuga Matt	CFO & Chief Business Officer	Jan 06 '26	Sale	1.97	5,100	10,028	222,644	Jan 07 09:31 PM
Zuga Matt	CFO & Chief Business Officer	Jan 05 '26	Sale	1.96	4,000	7,842	227,744	Jan 07 09:31 PM
Siemers Eric	Chief Medical Officer	Jan 06 '26	Sale	1.97	6,834	13,442	159,464	Jan 07 09:31 PM
Siemers Eric	Chief Medical Officer	Jan 05 '26	Sale	1.96	4,000	7,835	166,298	Jan 07 09:31 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 07 '26	Sale	1.99	37,755	74,981	619,982	Jan 07 09:31 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 06 '26	Sale	1.97	5,102	10,032	657,737	Jan 07 09:31 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 05 '26	Sale	1.97	4,649	9,163	662,839	Jan 07 09:31 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 07 '26	Sale	1.99	11,770	23,414	134,459	Jan 07 09:30 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 06 '26	Sale	1.97	10,898	21,438	146,229	Jan 07 09:30 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 05 '26	Sale	1.96	4,000	7,838	157,127	Jan 07 09:30 PM
Barton Russell	Chief Operating Officer	Jan 05 '26	Sale	1.96	4,000	7,832	132,117	Jan 07 09:30 PM
Barton Russell	Chief Operating Officer	Jan 06 '26	Sale	1.97	3,618	7,114	128,499	Jan 07 09:30 PM
Barton Russell	Chief Operating Officer	Jan 07 '26	Sale	1.99	1,700	3,378	126,799	Jan 07 09:30 PM
Schacterle Amy	Officer	Jan 07 '26	Proposed Sale	1.98	1,097	2,176		Jan 07 05:16 PM
Doherty James J.	Officer	Jan 07 '26	Proposed Sale	1.99	1,700	3,380		Jan 07 05:11 PM
Meisner Derek M	Officer	Jan 07 '26	Proposed Sale	1.99	11,770	23,415		Jan 07 05:08 PM
Barton Russell	Officer	Jan 07 '26	Proposed Sale	1.99	1,700	3,378		Jan 07 05:01 PM
Zuga Matt	Officer	Jan 07 '26	Proposed Sale	1.99	5,805	11,566		Jan 07 04:58 PM
OConnell Daniel Joseph	Officer	Jan 07 '26	Proposed Sale	1.99	37,755	74,981		Jan 07 04:49 PM
Meisner Derek M	Officer	Jan 06 '26	Proposed Sale	1.97	10,898	21,438		Jan 06 04:59 PM
Siemers Eric	Officer	Jan 05 '26	Proposed Sale	1.97	6,834	13,443		Jan 06 04:50 PM
Barton Russell	Officer	Jan 06 '26	Proposed Sale	1.97	3,618	7,114		Jan 06 04:47 PM
Zuga Matt	Officer	Jan 06 '26	Proposed Sale	1.97	5,100	10,028		Jan 06 04:43 PM
OConnell Daniel Joseph	Officer	Jan 06 '26	Proposed Sale	1.97	5,102	10,031		Jan 06 04:40 PM
Meisner Derek M	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,838		Jan 05 05:17 PM
Siemers Eric	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,835		Jan 05 05:09 PM
Barton Russell	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,832		Jan 05 05:06 PM
Zuga Matt	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,842		Jan 05 05:03 PM
OConnell Daniel Joseph	Officer	Jan 05 '26	Proposed Sale	1.97	4,649	9,163		Jan 05 04:48 PM

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

CEO & DirectorMr. Daniel J. O'Connell M.B.A.

President & Chief Development OfficerDr. James Doherty Ph.D.

CFO & Chief Business OfficerMr. Matt Zuga

Co-FounderDr. Grant A. Krafft Ph.D.

Co-FounderDr. Caleb E. Finch Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABOS

Acumen Pharmaceuticals Inc

Upgrade your Finviz experience